Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 14, 2020
Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents...
-
Jan 2, 2020Conference schedule includes 38th Annual J.P. Morgan Healthcare Conference and Investor Update at NANS 2020
Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman...
-
Dec 13, 2019U.S. Food and Drug Administration Granted EXALT Model D Single-Use Duodenoscope Breakthrough Device Designation, Expediting Physicians' Access to a New, Sterile Device for Each Patient
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde...
-
Nov 21, 2019
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two investor conferences this December. On Wednesday, December 4, 2019, Susie Lisa, vice president, Investor Relations, and...
-
Nov 12, 2019
Boston Scientific Corporation (NYSE: BSX) (the "Company") completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027 (the "Notes"). The Company has...
-
Nov 6, 2019
Boston Scientific Corporation (the "Company") (NYSE: BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's...
-
Nov 5, 2019
Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...
-
Nov 5, 2019Late-breaking clinical trial data demonstrate high rates of primary patency and significantly lower rates of clinically-driven target lesion revascularization for peripheral drug-eluting device portfolio
Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at...
-
Nov 5, 2019
Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...
-
Nov 1, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in four conferences, including one industry conference and three investor conferences, this month. On November 5, 2019, Jeff Mirviss,...